Ken Griffin Exact Sciences Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $4.46 Million - $7.45 Million	105,200 Added 26.91%	496,100 $33.8 Million
Q2 2024 Aug 14, 2024	SELL	$41.33 - $74.26 $14.2 Million - $25.6 Million	-344,300 Reduced 46.83%	390,900 $16.5 Million
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $26.8 Million - $35.1 Million	475,700 Added 183.31%	735,200 $50.8 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $631,942 - $810,204	10,700 Added 4.3%	259,500 $19.2 Million
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $2.16 Million - $3.24 Million	-32,700 Reduced 11.62%	248,800 $17 Million
Q2 2023 Aug 14, 2023	BUY	$62.68 - $95.05 $5.99 Million - $9.09 Million	95,600 Added 51.43%	281,500 $26.4 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $3.77 Million - $5.65 Million	-79,900 Reduced 30.06%	185,900 $12.6 Million
Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $2.72 Million - $4.76 Million	-89,600 Reduced 25.21%	265,800 $13.2 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $2.41 Million - $3.72 Million	75,300 Added 26.88%	355,400 $11.5 Million

671

163M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.73B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.